Submitting promotional pieces to the Office of Prescription Drug Promotion for advisory comments, and then seeking further ...

At AASLD, Madrigal is presenting real-world data supporting the benefits of long-term Rezdiffra treatment, while it plans a ...

BD’s fiscal fourth-quarter revenue rose 5.6% on a currency-neutral basis to $5.27bn, and adjusted EPS climbed 27.3% to $4.15.

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. More than 40 documents ...

The wellness takeover” across regions and demographics as consumers worldwide rank wellness second-highest priority, behind ...

The EGFRxMET-targeting bispecific antibody won accelerated approval from the US FDA for head and neck squamous cell carcinoma ...

CMS decided a one-dose gene therapy counts as just a year of treatment when its price is compared with monthly drugs, which ...

Licensing remains a strategic R&D avenue for major developers even as the M&A market begins to recover. In Vivo has ...

Cardinal Health raised its fiscal 2027 non-GAAP EPS guidance to $12.80–$13 after first-quarter non-GAAP EPS rose to $3.26, ...

Asia-Pacific OTC sales grew just 1.5% in the 12 months to June, IQVIA told the APSMI Summit in Bali, with cough and cold the ...

Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their ...

Europe’s research-based association warns that EU pharmaceutical sandbox plans could face fresh scrutiny from national ...